Файловый архив студентов. Файловый архив студентов.
1330 вузов, 5508 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5625_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
17 Мб
Скачать
☆
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
57 Zhang, H., Fu, H., Luallen, R.J. etal. (2015). Antibodies elicited by yeast
glycoproteins recognize HIV1 virions and potently neutralize virions with high mannose Nglycans. Vaccine 33 (39): 5140–5147.
58 Walker, L.M., Phogat, S.K., ChanHui, P.Y. etal. (2009). Broad and potent
neutralizing antibodies from an African donor reveal a new HIV1 vaccine target. Science 326 (5950): 285–289.
59 Bonsignori, M., Hwang, K.K., Chen, X. etal. (2011). Analysis of a clonal lineage
of HIV1 envelope V2/V3 conformational epitopespecific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology 85 (19): 9998–10009.
60 Walker, L.M., Huber, M., Doores, K.J. etal. (2011). Broad neutralization coverage
of HIV by multiple highly potent antibodies. Nature 477 (7365): 466–470.
61 DoriaRose, N.A., Schramm, C.A., Gorman, J. etal. (2014). Developmental
pathway for potent V1V2directed HIVneutralizing antibodies. Nature 509 (7498): 55–62.
62 DoriaRose, N.A., Bhiman, J.N., Roark, R.S. etal. (2016). New member of the
V1V2directed CAP256VRC26lineage that shows increased breadth and exceptional potency. Journal of Virology 90 (1): 76–91.
63 Sok, D., van Gils, M.J., Pauthner, M. etal. (2014). Recombinant HIV envelope
trimer selects for quaternarydependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences 111 (49): 17624–17629.
64 Doores, K.J. and Burton, D.R. (2010). Variable loop glycan dependency of the
broad and potent HIV1neutralizing antibodies PG9 and PG16. Journal of Virology 84 (20): 10510–10521.
65 McLellan, J.S., Pancera, M., Carrico, C. etal. (2011). Structure of HIV1 gp120 V1/
V2 domain with broadly neutralizing antibody PG9. Nature 480 (7377): 336–343.
66 Amin, M.N., McLellan, J.S., Huang, W. etal. (2013). Synthetic glycopeptides reveal
the glycan specificity of HIVneutralizing antibodies. Nature Chemical Biology 9 (8): 521–526.
67 Toonstra, C., Amin, M.N., and Wang, L.X. (2016). Siteselective chemoenzymatic
glycosylation of an HIV1 polypeptide antigen with two distinct Nglycans via an orthogonal protecting group strategy. The Journal of Organic Chemistry 81 (15): 6176–6185.
68 Pancera, M., ShahzadulHussan, S., DoriaRose, N.A. etal. (2013). Structural
basis for diverse Nglycan recognition by HIV1–neutralizing V1–V2–directed antibody PG16. Nature Structural & Molecular Biology 20 (7): 804–813.
69 Shivatare, S.S., Chang, S.H., Tsai, T.I. etal. (2016). Modular synthesis of
Nglycans and arrays for the heteroligand binding analysis of HIV antibodies. Nature Chemistry 8 (4): 338–346.
70 Shivatare, V.S., Shivatare, S.S., Lee, C.C.D. etal. (2018). Unprecedented role of
hybrid N glycans as ligands for HIV1 broadly neutralizing antibodies. Journal of the American Chemical Society 140 (15): 5202–5210.
71 Aussedat, B., Vohra, Y., Park, P.K. etal. (2013). Chemical synthesis of highly
congested gp120 V1V2 Nglycopeptide antigens for potential HIV1directed vaccines. Journal of the American Chemical Society 135 (35): 13113–13120.
101
3 Carbohydrate-Based Antiviral Vaccines
102
72 Alam, S.M., Dennison, S.M., Aussedat, B. etal. (2013). Recognition of synthetic
glycopeptides by HIV1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences 110 (45): 18214–18219.
73 Pejchal, R., Doores, K.J., Walker, L.M. etal. (2011). A potent and broad
neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (6059): 1097–1103.
74 Mouquet, H., Scharf, L., Euler, Z. etal. (2012). Complextype Nglycan recognition
by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences 109 (47): E3268–E3277.
75 Pantophlet, R., Trattnig, N., Murrell, S. etal. (2017). Bacterially derived synthetic
mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Nature Communications 8 (1): 1601.
76 Cai, H., Orwenyo, J., Guenaga, J. etal. (2017). Synthetic multivalent V3
glycopeptides display enhanced recognition by glycandependent HIV1 broadly neutralizing antibodies. Chemical Communications 53 (39): 5453–5456.
77 Orwenyo, J., Cai, H., Giddens, J. etal. (2017). Systematic synthesis and binding
study of HIV V3 glycopeptides reveal the fine epitopes of several broadly neutralizing antibodies. ACS Chemical Biology 12 (6): 1566–1575.
78 Cai, H., Orwenyo, J., Giddens, J.P. etal. (2017). Synthetic threecomponent HIV1
V3 glycopeptide immunogens induce glycandependent antibody responses. Cell Chemical Biology 24 (12): 1513–1522.
79 Cai, H., Zhang, R., Orwenyo, J. etal. (2018). Multivalent antigen presentation
enhances the immunogenicity of a synthetic threecomponent HIV1 V3 glycopeptide vaccine. ACS Central Science 4 (5): 582–589.
80 Cai, H., Zhang, R.S., Orwenyo, J. etal. (2018). Synthetic HIV V3 glycopeptide
immunogen carrying a N334 Nglycan induces glycandependent antibodies with promiscuous site recognition. Journal of Medicinal Chemistry 61 (22): 10116–10125.
81 Alam, S.M., Aussedat, B., Vohra, Y. etal. (2017). Mimicry of an HIV broadly
neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine 9 (381): eaai7521.
82 Francica, J.R., Laga, R., Lynn, G.M. etal. (2019). Star nanoparticles delivering
HIV1 peptide minimal immunogens elicit nearnative envelope antibody responses in nonhuman primates. PLoS Biology 17 (6): e3000328.
83 Haynes, B.F., Kelsoe, G., Harrison, S.C., and Kepler, T.B. (2012). Bcell–lineage
immunogen design in vaccine development with HIV1 as a case study. Nature Biotechnology 30 (5): 423–433.
84 Alexander, D.J. (2000). A review of avian influenza in different bird species.
Veterinary Microbiology 74: 3–13.
85 Zhuang, Q., Wang, S., Liu, S. etal. (2019). Diversity and distribution of type A
influenza viruses: an updated panorama analysis based on protein sequences. Virology Journal 16 (1): 85.
86 Wagner, R., Matrosovich, M., and Klenk, H. (2002). Functional balance between
haemagglutinin and neuraminidase in influenza virus infections. Reviews in Medical Virology 12: 159–166.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
87 Klenk, H.D., Wagner, R., Heuer, D., and Wolff, T. (2002). Importance of
hemagglutinin glycosylation for the biological functions of influenza virus. Virus Research 82: 73–75.
88 De Jong, N.M.C., Aartse, A., Van Gils, M.J., and Eggink, D. (2020). Development
of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains. Expert Review of Vaccines 19 (6): 563–577.
89 Wilson, I.A., Shekel, J.J., and Wiley, D.C. (1981). Structure of the haemagglutinin
membrane glycoprotein of influenza virus at 3A° resolution. Nature 289: 366–373.
90 Steinhauer, D.A. (1999). Role of hemagglutinin cleavage for the pathogenicity of
influenza virus. Virology 258 (1): 1–20.
91 Worch, R. (2014). Structural biology of the influenza virus fusion peptide. Acta
Biochimica Polonica 61 (3): 421–426.
92 Bouvier, N.M. and Palese, P. (2008). The biology of influenza viruses. Vaccine 26:
D49–D53.
93 Coudeville, L., Bailleux, F., Riche, B. etal. (2010). Relationship between
haemagglutinationinhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian randomeffects model. BMC Medical Research Methodology 10: 18.
94 Bullard, B.L. and Weaver, E.A. (2021). Strategies targeting hemagglutinin as a
universal influenza vaccine. Vaccine 9 (3): 257.
95 Eggink, D., Goff, P.H., and Palese, P. (2014). Guiding the immune response against
influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. Journal of Virology 88 (1): 699–704.
96 Lin, S.C., Liu, W.C., Jan, J.T., and Wu, S.C. (2014). Glycan masking of
hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One 9 (3): e92822.
97 Lin, S.C., Lin, Y.F., Chong, P., and Wu, S.C. (2012). Broader neutralizing
antibodies against H5N1 viruses using primeboost immunization of hyperglycosylated hemagglutinin DNA and viruslike particles. PLoS One 7 (6): 1–8.
98 Nguyen, Q.T. and Choi, Y.K. (2021). Targeting antigens for universal influenza
vaccine development. Viruses 13 (6): 973.
99 Ulmer, J.B., DeWitt, C.M., Chastain, M. etal. (1999). Enhancement of DNA
vaccine potency using conventional aluminum adjuvants. Vaccine 18: 18–28.
100 Tregoning, J.S., Russell, R.F., and Kinnear, E. (2018). Adjuvanted influenza
vaccines. Human Vaccines & Immunotherapeutics 14: 550–564.
101 Hung, J.T., Tsai, Y.C., Der Lin, W. etal. (2014). Potent adjuvant effects of novel
NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1influenza virus. Antiviral Research 107 (1): 110–118.
102 Natori, T., Koezuka, Y., and Higa, T. (1993). Agelasphins, novel
αgalactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Letters 34 (35): 5591–5592.
103
3 Carbohydrate-Based Antiviral Vaccines
104
103 Morita, M., Motoki, K., Akimoto, K. etal. (1995). Structureactivity relationship of
αgalactosylceramides against B16bearing mice. Journal of Medicinal Chemistry 38 (12): 2176–2187.
104 Guillonneau, C., Mintern, J.D., Hubert, F.X. etal. (2009). Combined NKT cell
activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proceedings of the National Academy of Sciences of the United States of America 106: 3330–3335.
105 Artiaga, B.L., Yang, G., Hackmann, T.J. etal. (2016). αgalactosylceramide protects
swine against influenza infection when administered as a vaccine adjuvant. Scientific Reports 6: 23593.
106 Dölen, Y., Kreutz, M., Gileadi, U. etal. (2016). Codelivery of PLGA encapsulated
invariant NKT cell agonist with antigenic protein induce strong T cellmediated antitumor immune responses. Oncoimmunology 5 (1): e1068493.
107 Lang, S. and Huang, X. (2020). Carbohydrate conjugates in vaccine developments.
Frontiers in Chemistry 8 (April): 1–25.
108 Anderson, R.J., Li, J., Kedzierski, L. etal. (2017). Augmenting influenzaspecific
T cell memory generation with a natural killer T celldependent glycolipidpeptide vaccine. ACS Chemical Biology 12 (11): 2898–2905.
109 Wilkinson, T.M., Li, C.K., Chui, C.S. etal. (2012). Preexisting influenzaspecific
+
T cells correlate with disease protection against influenza challenge in
CD4 humans. Nature Medicine 18: 274–280.
110 AbdelMotal, U.M., Guay, H.M., Wigglesworth, K. etal. (2007). Immunogenicity
of influenza virus vaccine is increased by antigalmediated targeting to antigen presenting cells. Journal of Virology 81 (17): 9131–9141.
111 Henion, T.R., Gerhard, W., Anaraki, F., and Galili, U. (1997). Synthesis of αgal
epitopes on influenza virus vaccines, by recombinant α1,3galactosyltransferase, enables the formation of immune complexes with the natural antiGal antibody. Vaccine 15 (11): 1174–1182.
112 von Itzstein, M. (2007). The war against influenza: discovery and development of
sialidase inhibitors. Nature Reviews. Drug Discovery 6: 967–974.
113 Wohlbold, T.J. and Krammer, F. (2014). In the shadow of hemagglutinin: a
growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6 (6): 2465–2494.
114 Chen, Y.Q., Wohlbold, T.J., Zheng, N.Y. etal. (2018). Influenza infection in
humans induces broadly crossreactive and protective neuraminidasereactive antibodies. Cell 173 (2): 417–429.e10.
115 Gilchuk, I.M., Bangaru, S., Gilchuk, P. etal. (2019). Influenza H7N9 virus
neuraminidasespecific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice. Cell Host & Microbe 26 (6): 715–728.
116 Trombetta, C.M. and Montomoli, E. (2016). Influenza immunology evaluation and
correlates of protection: a focus on vaccines. Expert Review of Vaccines 15 (8): 967–976.
117 Krammer, F., Fouchier, R.A.M., Eichelberger, M.C. etal. (2018). NAction! how can
neuraminidasebased immunity contribute to better influenza virus vaccines? mBio 9 (2): e02332–e02317.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
118 Wan, H., Yang, H., Shore, D.A. etal. (2015). Structural characterization of a
protective epitope spanning A(H1N1)pdm09influenza virus neuraminidase monomers. Nature Communications 6: 6114.
119 Zhu, X., Turner, H.L., Lang, S. etal. (2019). Structural basis of protection against
H7N9influenza virus by human antiN9neuraminidase antibodies. Cell Host & Microbe 26 (6): 729–738.e4.
120 Bachelder, E.M., Beaudette, T.T., Broaders, K.E. etal. (2008). Acetalderivatized
dextran: an acidresponsive biodegradable material for therapeutic applications. Journal of the American Chemical Society 130 (32): 10494–10495.
121 Bachelder, E.M., Beaudette, T.T., Broaders, K.E. etal. (2010). In vitro analysis of
acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Molecular Pharmaceutics 7 (3): 826–835.
122 Junkins, R.D., Gallovic, M.D., Johnson, B.M. etal. (2018). A robust microparticle
platform for a STINGtargeted adjuvant that enhances both humoral and cellular immunity during vaccination. Journal of Controlled Release 270: 1–13.
123 Chen, N., Johnson, M.M., Collier, M.A. etal. (2018). Tunable degradation of
acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. Journal of Controlled Release 273: 147–159.
124 Matrosovich, M. and Klenk, H.D. (2003). Natural and synthetic sialic acid
containing inhibitors of influenza virus receptor binding. Reviews in Medical Virology 13 (2): 85–97.
125 Bhatia, S., Dimde, M., and Haag, R. (2014). Multivalent glycoconjugates as
vaccines and potential drug candidates. MedChemComm 5 (7): 862–878.
126 Lees, W.J., Spaltenstein, A., Kingerywood, J.E., and Whitesides, G.M. (1994).
Polyacrylamides bearing pendant asialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological system. Journal of Medicinal Chemistry 37 (20): 3419–3433.
127 Sigal, G.B., Mammen, M., Dahmann, G., and Whitesides, G.M. (1996).
Polyacrylamides bearing pendant αsialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. Journal of the American Chemical Society 118: 3789–3800.
128 Mammen, M., Dahmann, G., and Whitesides, G.M. (1995). Effective inhibitors of
hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. Journal of Medicinal Chemistry 38 (21): 4179–4190.
129 Gambaryan, A.S., Tuzikov, A.B., Chinarev, A.A. etal. (2002). Polymeric inhibitor
of influenza virus attachment protects mice from experimental influenza infection. Antiviral Research 55 (1): 201–205.
130 Kwon, S.J., Na, D.H., Kwak, J.H. etal. (2017). Nanostructured glycan architecture
is important in the inhibition of influenza A virus infection. Nature Nanotechnology 12 (1): 48–54.
131 Papp, I., Sieben, C., Ludwig, K. etal. (2010). Inhibition of influenza virus infection by
multivalent sialicacid functionalized gold nanoparticles. Small 6 (24): 2900–2906.
105
3 Carbohydrate-Based Antiviral Vaccines
106
132 Vonnemann, J., Sieben, C., Wolff, C. etal. (2014). Virus inhibition induced by
polyvalent nanoparticles of different sizes. Nanoscale 6 (4): 2353–2360.
133 Papp, I., Sieben, C., Sisson, A.L. etal. (2011). Inhibition of influenza virus activity
by multivalent glycoarchitectures with matched sizes. ChemBioChem 12 (6): 887–895.
134 Lee, C.M., Weight, A.K., Haldar, J. etal. (2012). Polymerattached zanamivir
inhibits synergistically both early and late stages of influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America 109 (50): 20385–20390.
135 Lauer, G.M. and Walker, B.D. (2001). Hepatitis C virus infection. The New England
Journal of Medicine 345 (1): 41–52.
136 The Polaris Observatory HCV Collaborators (2017). Global prevalence and
genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology 2 (3): 161–176.
137 Dubuisson, J. (2007). Hepatitis C virus proteins. World Journal of Gastroenterology
13 (17): 2406–2415.
138 Goffard, A. (2003). Glycosylation of hepatits C virus envelope proteins. Biochemie
85 (3, 4): 295–301.
139 Zhang, M., Gaschen, B., Blay, W. etal. (2004). Tracking global patterns of Nlinked
glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14 (12): 1229–1246.
140 Op De Beeck, A., Cocquerel, L., and Dubuisson, J. (2001). Biogenesis of hepatitis
C virus envelope glycoproteins. The Journal of General Virology 82: 2589–2595.
141 Pileri, P., Uematsu, Y., Campagnoli, S. etal. (1998). Binding of hepatitis C virus to
CD81. Science 282 (5390): 938–941.
142 Scarselli, E., Ansuini, H., Cerino, R. etal. (2002). The human scavenger receptor
class B type I is a novel candidate receptor for the hepatitis C virus. The EMBO Journal 21 (19): 5017–5025.
143 Ball, J.K., Tarr, A.W., and McKeating, J.A. (2014). The past, present and future of
neutralizing antibodies for hepatitis C virus. Antiviral Research 105 (1): 100–111.
144 Helle, F., Goffard, A., Morel, V. etal. (2007). The neutralizing activity of anti
hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. Journal of Virology 81 (15): 8101–8111.
145 Cormier, E.G., Durso, R.J., Tsamis, F. etal. (2004). LSIGN (CD209L) and DC
SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 101 (39): 14067–14072.
146 Iacob, R.E., Perdivara, I., Przybylski, M., and Tomer, K.B. (2008). Mass
spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of Nglycans. Journal of the American Society for Mass Spectrometry 19 (3): 428–444.
147 Bertaux, C., Daelemans, D., Meertens, L. etal. (2007). Entry of hepatitis C virus
and human immunodeficiency virus is selectively inhibited by carbohydrate binding agents but not by polyanions. Virology 366 (1): 40–50.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
148 Helle, F., Wychowski, C., VuDac, N. etal. (2006). CyanovirinN inhibits hepatitis
C virus entry by binding to envelope protein glycans. The Journal of Biological Chemistry 281 (35): 25177–25183.
149 Li, D., von Schaewen, M., Wang, X. etal. (2016). Altered glycosylation patterns
increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. Journal of Virology 90 (23): 10486–10498.
150 Peters, C.J. and LeDuc, J.W. (1999). An introduction to Ebola: the virus and the
disease. The Journal of Infectious Diseases 179 (Suppl 1): ix–xvi.
151 Kuhn, J.H., Becker, S., Ebihara, H. etal. (2010). Proposal for a revised taxonomy of
the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Archives of Virology 155 (12): 2083–2103.
152 WHO Ebola Response Team (2016). After Ebola in West Africa: unpredictable
risks, preventable epidemics. The New England Journal of Medicine 375 (6): 587–596.
153 Yang, Z.Y., Delgado, R., Xu, L. etal. (1998). Distinct cellular interactions of
secreted and transmembrane Ebola virus glycoproteins. Science 279 (5353): 1034–1037.
154 Medaglini, D. and Siegrist, C.A. (2017). Immunomonitoring of human responses
to the rVSVZEBOV Ebola vaccine. Current Opinion in Virology 23: 88–94.
155 Agnandji, S.T. and Loembe, M.M. (2021). Ebola vaccines for mass immunisation
in affected regions. The Lancet Infectious Diseases S14733099 (21): 00226–00227.
156 Lennemann, N.J., Rhein, B.A., Ndungo, E. etal. (2014). Comprehensive functional
analysis of Nlinked glycans on ebola virus GP1. mBio 5 (1): e00862–e00813.
157 Michelow, I.C., Lear, C., Scully, C. etal. (2011). Highdose mannosebinding lectin
therapy for Ebola virus infection. The Journal of Infectious Diseases 203 (2): 175–179.
158 Yu, D.S., Weng, T.H., Wu, X.X. etal. (2017). The lifecycle of the Ebola virus in host
cells. Oncotarget 8 (33): 55750–55759.
159 Dowling, W., Thompson, E., Badger, C. etal. (2007). Influences of glycosylation on
antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. Journal of Virology 81 (4): 1821–1837.
160 Ou, W., Delisle, J., Jacques, J. etal. (2012). Induction of ebolavirus crossspecies
immunity using retroviruslike particles bearing the Ebola virus glycoprotein lacking the mucinlike domain. Virology Journal 9: 1–13.
161 Tshiani Mbaya, O., Mukumbayi, P., and Mulangu, S. (2021). Review: insights on
current FDAapproved monoclonal antibodies against Ebola virus infection. Frontiers in Immunology 12: 721328.
162 Iversen, P.L., Kane, C.D., Zeng, X. etal. (2020). Recent successes in therapeutics
for Ebola virus disease: no time for complacency. The Lancet Infectious Diseases 20 (9): e231–e237.
163 Warren, T.K., Wells, J., Panchal, R.G. etal. (2014). Protection against filovirus
diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature 508 (7496): 402–405.
107
3 Carbohydrate-Based Antiviral Vaccines
108
164 Julander, J., Demarest, J., Taylor, R. etal. (2021). An update on the progress of
galidesivir (BCX4430), a broadspectrum antiviral. Antiviral Research 195: 105180.
165 Mulangu, S., Dodd, L.E., Davey, R.T. etal. (2019). A randomized, controlled trial
of Ebola virus disease therapeutics. The New England Journal of Medicine 381: 2293–2303.
166 Simmons, G., Reeves, J.D., Grogan, C.C. etal. (2003). DCSIGN and DCSIGNR
bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305 (1): 115–123.
167 Baribaud, F., Doms, R.W., and Pöhlmann, S. (2002). The role of DCSIGN and
DCSIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? Expert Opinion on Therapeutic Targets 6 (4): 423–431.
168 Bhatia, S., Camacho, L.C., and Haag, R. (2016). Pathogen inhibition by
multivalent ligand architectures. Journal of the American Chemical Society 138 (28): 8654–8666.
169 Illescas, B.M., Rojo, J., Delgado, R., and Martín, N. (2017). Multivalent
glycosylated nanostructures to inhibit Ebola virus infection. Journal of the American Chemical Society 139 (17): 6018–6025.
170 RibeiroViana, R., SánchezNavarro, M., Luczkowiak, J. etal. (2012). Viruslike
glycodendrinanoparticles displaying quasiequivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nature Communications 3: 1303.
171 Muñoz, A., Sigwalt, D., Illescas, B.M. etal. (2016). Synthesis of giant globular
multivalent glycofullerenes as potent inhibitors in a model of Ebola virus infection. Nature Chemistry 8 (1): 50–57.
172 Zhou, P., Yang, X.L., Wang, X.G. etal. (2020). A pneumonia outbreak associated
with a new coronavirus of probable bat origin. Nature 579 (7798): 270–273.
173 Du, L., He, Y., Zhou, Y. etal. (2009). The spike protein of SARSCoV– a target for
vaccine and therapeutic development. Nature Reviews. Microbiology 7 (3): 226–236.
174 Satarker, S. and Nampoothiri, M. (2020). Structural proteins in severe acute
respiratory syndrome coronavirus2. Archives of Medical Research 51 (6): 482–491.
175 Watanabe, Y., Allen, J.D., Wrapp, D. etal. (2020). Sitespecific glycan analysis of
the SARSCoV2 spike. Science 369 (6501): 330–333.
176 Shajahan, A., Supekar, N.T., Gleinich, A.S., and Azadi, P. (2020). Deducing the
N and O glycosylation profile of the spike protein of novel coronavirus SARS CoV2. Glycobiology 30 (12): 981–988.
177 Huang, Y., Yang, C., Xu, X.F. etal. (2020). Structural and functional properties of
SARSCoV2 spike protein: potential antivirus drug development for COVID19. Acta Pharmacologica Sinica 41 (9): 1141–1149.
178 Casalino, L., Gaieb, Z., Goldsmith, J.A. etal. (2020). Beyond shielding: the roles
of glycans in the SARSCoV2 spike protein. ACS Central Science 6 (10): 1722–1734.
179 Andersen, K.G., Rambaut, A., Lipkin, W.I. etal. (2020). The proximal origin of
SARSCoV2. Nature Medicine 26: 450–452.
180 Lan, J., Ge, J., Yu, J. etal. (2020). Structure of the SARSCoV2 spike receptor
binding domain bound to the ACE2 receptor. Nature 581 (7807): 215–220.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
181 Yi, C., Sun, X., Ye, J. etal. (2020). Key residues of the receptor binding motif in the
spike protein of SARSCoV2 that interact with ACE2 and neutralizing antibodies. Cellular & Molecular Immunology 17 (6): 621–630.
182 Liu, C., Zhou, Q., Li, Y. etal. (2020). Research and development on therapeutic
agents and vaccines for COVID19 and related human coronavirus diseases. ACS Central Science 6 (3): 315–331.
183 Jiang, S., Hillyer, C., and Du, L. (2020). Neutralizing antibodies against SARS
CoV2 and other human coronaviruses. Trends in Immunology 41 (5): 355–359.
184 Wang, D. (2020). Coronaviruses’ sugar shields as vaccine candidates. Current
Trends in Immunology 21: 17–23.
185 Watanabe, Y., Berndsen, Z.T., Raghwani, J. etal. (2020). Vulnerabilities in
coronavirus glycan shields despite extensive glycosylation. Nature Communications 11 (1): 2688.
186 Duan, L., Zheng, Q., Zhang, H. etal. (2020). The SARSCoV2 spike glycoprotein
biosynthesis, structure, function, and antigenicity: Implications for the design of spikebased vaccine immunogens. Frontiers in Immunology 11: 576622.
187 Kumbhar, P.S., Pandya, A.K., Manjappa, A.S. etal. (2020). Carbohydratesbased
diagnosis, prophylaxis and treatment of infectious diseases: special emphasis on COVID19. Carbohydrate Polymer Technologies and Applications 2: 100052.
188 Galili, U. (2020). Amplifying immunogenicity of prospective Covid19 vaccines by
glycoengineering the coronavirus glycanshield to present αgal epitopes. Vaccine 38 (42): 6487–6499.
189 ValdesBalbin, Y., SantanaMederos, D., Paquet, F. etal. (2021). Molecular aspects
concerning the use of the SARSCoV2 receptor binding domain as a target for preventive vaccines. ACS Central Science 7 (5): 757–767.
190 Yang, J., Wang, W., Chen, Z. etal. (2020). A vaccine targeting the RBD of the S
protein of SARSCoV2induces protective immunity. Nature 586: 572–577.
191 ValdesBalbin, Y., SantanaMederos, D., Quintero, L. etal. (2021). SARSCoV2
RBDtetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies. ACS Chemical Biology 16 (7): 1223–1233.
192 ToledoRomaní, M.E., GarcíaCarmenate, M., etal., GarcíaRivera, D., Vérez
Bencomo, V., SOBERANA Phase 3 team. (2023). Safety and efficacy of the two doses conjugated proteinbased SOBERANA02 COVID19 vaccine and of a heterologous threedose combination with SOBERANAPlus: a doubleblind, randomised, placebocontrolled phase 3 clinical trial. The Lancet Regional Health– Americas, 18: 100423 doi.org/10.1101/2021.10.31.21265703.
193 Ye, F., Zhao, J., Xu, P. etal. (2021). Synthetic homogeneous glycoforms of the
SARSCoV2 spike receptorbinding domain reveals different binding profiles of monoclonal antibodies. Angewandte Chemie, International Edition 60 (23): 12904–12910.
194 Pifferi, C., Fuentes, R., and FernándezTejada, A. (2021). Natural and synthetic
carbohydratebased vaccine adjuvants and their mechanisms of action. Nature Reviews Chemistry 5 (3): 197–216.
195 Schijns, V., Majhen, D., Van Der Ley, P. etal. (2021). Rational vaccine design in
times of emerging diseases: the critical choices of immunological correlates of protection, vaccine antigen and immunomodulation. Pharmaceutics 13 (4): 501.
109
3 Carbohydrate-Based Antiviral Vaccines
110
196 Kensil, C.R. (1996). Saponins as vaccine adjuvants. Critical Reviews in Therapeutic
Drug Carrier Systems 13: 1–55.
197 LacailleDubois, M.A. (2019). Updated insights into the mechanism of action and
clinical profile of the immunoadjuvant QS21: a review. Phytomedicine 60: 152905.
198 Wang, P. (2021). Natural and synthetic saponins as vaccine adjuvants. Vaccine
9 (3): 1–18.
199 Didierlaurent, A.M., Laupèze, B., Di Pasquale, A. etal. (2017). Adjuvant system
AS01: helping to overcome the challenges of modern vaccines. Expert Review of Vaccines 16 (1): 55–63.
200 Bengtsson, K.L., Morein, B., and Osterhaus, A.D. (2011). ISCOM technologybased
TM
Matrix M
adjuvant: success in future vaccines relies on formulation. Expert
Review of Vaccines 10 (4): 401–403.
201 Bengtsson, K.L., Karlsson, K.H., Magnusson, S.E. etal. (2013). MatrixM
adjuvant: enhancing immune responses by “setting the stage” for the antigen. Expert Review of Vaccines 12 (8): 821–823.
202 Tian, J.H., Patel, N., Haupt, R. etal. (2021). SARSCoV2 spike glycoprotein
vaccine candidate NVXCoV2373 immunogenicity in baboons and protection in mice. Nature Communications 12 (1): 372.
203 Heath, P.T., Galiza, E.P., Baxter, D.N. etal. (2021). Safety and efficacy of NVX
CoV2373 Covid19 vaccine. The New England Journal of Medicine 385 (13): 1172–1183.
204 Shinde, V., Bhikha, S., Hoosain, Z. etal. (2021). Efficacy of NVXCoV2373
Covid19 vaccine against the B.1.351 variant. The New England Journal of Medicine 384 (20): 1899–1909.
TM
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности